Nader Sanai
Clinical trials sponsored by Nader Sanai, explained in plain language.
Upcoming readouts
Trials from this sponsor expected to report results within the next 12 months.
- New drug aims to reach brain tumors in recurrent glioblastoma Results expected Sep 2026 (estimated)
- New smart drug takes aim at Hard-to-Treat brain cancers Results expected Jul 2027 (estimated)
- Can a new pill reach brain tumors and halt their growth? Results expected Jul 2027 (estimated)
-
Sound waves and drug team up against brain tumors
Disease control Stopped earlyThis early-phase trial tested a combination of a drug called aminolevulinic acid (ALA) and focused ultrasound to treat recurrent high-grade glioma, an aggressive brain cancer. The study aimed to see if this sonodynamic therapy could safely damage tumor cells. Only 10 participants…
Early phase 1 • Sponsor: Nader Sanai • Aim: Disease control
Last updated Jun 27, 2026 12:33 UTC
-
New way to deliver chemo directly to brain tumors tested in small study
Disease control Stopped earlyThis early-phase trial tested a single dose of the cancer drug temsirolimus, given directly into the brain's blood supply, for people with recurrent high-grade glioma (a fast-growing brain tumor). Only 5 participants were enrolled, and the study was terminated early. The main goa…
Early phase 1 • Sponsor: Nader Sanai • Aim: Disease control
Last updated Jun 27, 2026 12:33 UTC
-
Brain tumor drug penetration study halted early
Knowledge-focused Stopped earlyThis early-phase trial aimed to measure how much of the drug infigratinib reaches brain tumor tissue in people with recurrent high-grade glioma (a type of brain cancer). Only 7 participants were enrolled before the study was terminated. The main goal was to check drug levels in t…
Early phase 1 • Sponsor: Nader Sanai • Aim: Knowledge-focused
Last updated Jun 27, 2026 07:55 UTC